Vaccination for disease.
Recombinant virus vaccines that express a limited number of epitopes are currently being developed to prevent disease by changing the relative balance between viral spread and the immune response. Some circumstances, however, were found in infections with a noncytopathic virus in which vaccination caused disease; sensitive parameters included the genetic background of the host, the time or dose of infection, and the constituents of the vaccine. Thus, immunopathologic damage by T cells may be an unwanted consequence of vaccination with the new types of peptide or recombinant vaccines that are being investigated for the human immunodeficiency viruses and other pathogens.
Oehen
S
S
Laboratory for Experimental Pathology, University of Zürich, Switzerland.
Hengartner
H
H
Zinkernagel
R M
RM
D000818:Animals; D006023:Glycoproteins / Q000276:immunology; D006183:H-2 Antigens / Q000276:immunology; D007114:Immunization; D008216:Lymphocytic Choriomeningitis / Q000276:immunology* / Q000517:prevention & control; D008217:Lymphocytic choriomeningitis virus / Q000276:immunology* / Q000302:isolation & purification; D008578:Meninges / Q000276:immunology / Q000382:microbiology; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D009698:Nucleoproteins / Q000276:immunology; D013154:Spleen / Q000382:microbiology; D013601:T-Lymphocytes / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D014614:Vaccines, Synthetic / Q000009:adverse effects*; D014616:Vaccinia virus / Q000276:immunology; D014765:Viral Vaccines / Q000009:adverse effects*; D014777:Virus Diseases / Q000517:prevention & control*
D006023:Glycoproteins; D006183:H-2 Antigens; D009698:Nucleoproteins; D014614:Vaccines, Synthetic; D014765:Viral Vaccines